Article
Medicine, General & Internal
Courtney D. Dinardo, Harry P. Erba, Sylvie D. Freeman, Andrew H. Wei
Summary: Progress in acute myeloid leukaemia treatment has seen significant improvements in scientific understanding, prognostication tools, risk assessments, and incorporation of measurable residual disease into risk assessments. Recent updates in classification and recommendations by organizations such as WHO, ICC, and European LeukemiaNet have provided enhanced guidance for prognostic stratification and treatment response assessment. There have also been advancements in treatment options, leading to improved outcomes for both newly diagnosed and relapsed patients.
Article
Medical Laboratory Technology
Xiaoling Wen, Ruoqi Li, Xialin Zhang, Jiahong Zhai, Suxia Yang, Yaozi Wang, Yanhong Tan, Zhifang Xu, Linhua Yang, Ruijuan Zhang
Summary: The prognostic significance of early high platelet (PLT) values in patients with de novo non-M3 acute myeloid leukemia (AML) who achieved first complete remission (CR) was explored in this study. The results showed that early high PLT count recovery at first CR is a positive prognostic marker for survival outcomes in non-adverse-risk AML patients.
JOURNAL OF CLINICAL LABORATORY ANALYSIS
(2022)
Editorial Material
Hematology
Luca Castagna, Katia Patti, Antonino Mule
Summary: Transplantation from haploidentical donors is commonly used, and cord blood reduction is considered as an alternative donor. Matsuda and colleagues' study suggests that cord blood is still a feasible option for allogeneic transplantation in advanced acute myeloid leukemia.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Haohao Han, Yifang Yao, Hong Wang, Meng Zhou, Ziyan Zhang, Xiaoyan Xu, Jiaqian Qi, Yuejun Liu, Depei Wu, Yue Han
Summary: This study suggests that NOTCH mutations (NOTCHmut) may serve as an indicator for poor prognosis of acute myeloid leukemia (AML). NOTCHmut is associated with low platelet count and coexistence with other mutations. The presence of NOTCHmut is correlated with worse overall survival and relapse-free survival, especially within the intermediate-risk group according to the European Leukemia Net 2017 classification.
Article
Biochemistry & Molecular Biology
Xinai Liao, Ling Chen, Jingru Liu, Haoran Hu, Diyu Hou, Ruolan You, Xiaoting Wang, Huifang Huang
Summary: Patients with AML have poor prognoses due to heterogeneity and complex tumor microenvironment. This study analyzed the m(6)A modification features of 177 AML patients and identified three distinct m(6)A modification patterns related to biological functions, TME characteristics, and clinical outcomes. A risk score based on six m(6)A regulators was constructed and validated as an independent prognostic factor for AML. Four m(6)A regulators were found to be associated with AML survival and immune checkpoint inhibitor treatments. Understanding the m(6)A modification pattern can enhance our knowledge of AML and aid in the development of prognosis indicators and immunotherapeutic strategies.
Article
Cell Biology
Shenghao Hua, Tao Feng, Lei Yin, Qi Wang, Xuejun Shao
Summary: The study showed that NEDD9 overexpression in AML is associated with specific pathological classifications, genetic mutations, and prognosis. Patients with NEDD9 overexpression may benefit from HSCT. Additionally, miR-381 was identified as a potential therapeutic target by directly targeting NEDD9.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
(2021)
Article
Hematology
Liangshun You, Yi Liu, Nianci Chen, Li Zhu, Gaixiang Xu, Zuopo Lv, Yile Zhou, Chenying Li, Hongyan Tong, Jie Jin, Haitao Meng
Summary: We present a case of refractory AML patient achieving long-term complete remission after influenza A virus infection, and have functionally validated this finding in animal disease models. Our study also shows that infection with influenza A virus leads to an increase in helper T cells and the levels of multiple cytokines. These findings suggest that the anti-tumour effects induced by influenza A virus are closely associated with the modification of the immune response.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Editorial Material
Hematology
Milica Miladinovic, Jan-Henning Klusmann
Summary: You et al. report an exceptional case in which a refractory AML patient achieved long-term complete remission after Influenza A infection. Using mouse models, the researchers investigated the underlying immunological mechanisms and found that Influenza A virus infection decreased leukemia proliferation and improved survival in mice. These results suggest the therapeutic potential of Influenza A in the treatment of hematological cancers.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Multidisciplinary Sciences
Hope Mumme, Beena E. Thomas, Swati S. Bhasin, Upaasana Krishnan, Bhakti Dwivedi, Pruthvi Perumalla, Debasree Sarkar, Gulay B. Ulukaya, Himalee S. Sabnis, Sunita I. Park, Deborah Deryckere, Sunil S. Raikar, Melinda Pauly, Ryan J. Summers, Sharon M. Castellino, Daniel S. Wechsler, Christopher C. Porter, Douglas K. Graham, Manoj Bhasin
Summary: This study utilizes single-cell RNA sequencing to analyze pediatric AML bone marrow samples and identifies a 7-gene signature that can distinguish malignant cells at diagnosis and is associated with relapse or complete remission.
NATURE COMMUNICATIONS
(2023)
Article
Hematology
Xiang Zhang, Ziwei Wang, Jiewen Sun, Lixia Liu, Jiayue Qin, Aijie Huang, Min Yang, Yinjun Lou, Gusheng Tang, Liping Mao, Jiejin Qian, Juying Wei, Wenyuan Mai, Haitao Meng, Jianmin Yang, Hongyan Tong, Jianmin Wang, Wenjuan Yu, Xiong Ni, Jie Jin
Summary: As reported, SETD2 is frequently mutated in acute myeloid leukemia (AML), but there is limited knowledge about the specifics. In our study of 530 newly diagnosed AML patients, we found that SETD2 mutation affected 6.3% of patients and often co-occurred with IDH2, NRAS, and CEBPA mutations. Patients with SETD2 mutation had excellent therapeutic responses but did not have better survival time compared to other patients, possibly due to the high recurrence and mortality associated with additional mutations, such as NRAS mutation.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Editorial Material
Hematology
Pietro Merli
Summary: The report highlights the importance of pursuing a curative approach to improve prognosis in childhood acute myeloid leukemia.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Hematology
Weijia Fu, Yue Hu, Guihua Lu, Lili Xu, Lei Gao, Jie Chen, Li Chen, Gusheng Tang, Xiong Ni, Jianmin Yang
Summary: A standard salvage regimen for patients with AML who are not in CR after initial induction therapy is currently lacking. In this retrospective study, we investigated re-induction therapy for 151 AML patients who did not achieve CR after the initial course. The re-induction regimen did not correlate with CR rate after the second course, but patients had similar 5-year OS and EFS based on different re-induction regimens. ELN risk stratification independently predicted both OS and EFS among patients not in CR after the first course, while the re-induction regimen did not predict prognosis. Urgent salvage alloHSCT may improve the prognosis of refractory AML patients. In summary, the re-induction regimen did not significantly predict the prognosis of AML patients not in CR after the first course, highlighting the need for an efficient treatment algorithm for AML.
ANNALS OF HEMATOLOGY
(2023)
Article
Oncology
Caroline Engen, Monica Hellesoy, Tim Grob, Adil Al Hinai, Atle Brendehaug, Line Wergeland, Siv Lise Bedringaas, Randi Hovland, Peter J. M. Valk, Bjorn T. Gjertsen
Summary: This study investigated the distribution of FLT3-ITD variants in relation to clinical features and overall survival in adult AML patients. The findings showed that a significant proportion of patients had multiple mutated alleles and a correlation between low allele frequency and lower white blood cell count, as well as a correlation between higher allele frequency and poorer overall survival. Additionally, high ITD length was associated with inferior overall survival in one cohort.
MOLECULAR ONCOLOGY
(2021)
Review
Hematology
Elizabeth Herrity, Mariana Pinto Pereira, Dennis Dong Hwan Kim
Summary: This study describes the mechanistic diversity of relapse after hematopoietic stem cell transplantation and emphasizes the importance of these mechanisms in treatment selection and future research inspiration.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Kexiu Huang, Lei Wang, Yaling Zheng, Chunyan Yue, Xuedan Xu, Hongbo Chen, Rui Huang, Yuhua Li
Summary: Mutation of PHF6 gene may be associated with poor prognosis in AML, leading to poorer chemotherapy response and shorter survival.
Article
Hematology
Stephane de Botton, Pau Montesinos, Andre C. Schuh, Cristina Papayannidis, Paresh Vyas, Andrew H. Wei, Hans Ommen, Sergey Semochkin, Hee-Je Kim, Richard A. Larson, Jaime Koprivnikar, Olga Frankfurt, Felicitas Thol, Joerg Chromik, Jenny Byrne, Arnaud Pigneux, Xavier Thomas, Olga Salamero, Maria Belen Vidriales, Vadim Doronin, Hartmut Doehner, Amir T. Fathi, Eric Laille, Xin Yu, Maroof Hasan, Patricia Martin-Regueira, Courtney D. DiNardo
Summary: This study compared the efficacy of the oral IDH2 inhibitor enasidenib with conventional care regimens (CCR) in older patients with late-stage mutant-IDH2 AML. Enasidenib significantly improved event-free survival, time to treatment failure, overall response rate, hematologic improvement, and transfusion independence compared to CCR. However, there was no significant difference in overall survival, possibly due to early dropout and subsequent AML-directed therapies.
Article
Clinical Neurology
Anne Sophie L. Helligsoe, Louise T. Henriksen, Line Kenborg, Yasmin Lassen-Ramshad, Lisa M. Wu, Jeanette F. Winther, Henrik Hasle, Ali Amidi
Summary: This study examined neurocognitive function in childhood brain tumor survivors and its associations with quality of life (QoL) and symptom burden. The majority of survivors exhibited overall neurocognitive impairment, reduced QoL, and high symptom burden.
NEURO-ONCOLOGY PRACTICE
(2023)
Article
Hematology
Oriane Cedile, Marcus Hoy Hansen, Sara Kamuk Dahlmann, Thomas Kielsgaard Kristensen, Niels Abildgaard, Charlotte Guldborg Nyvold
Summary: Multiple myeloma, the second most common hematologic malignancy, remains incurable with high mortality rates. This study demonstrates the feasibility of using ultra-deep sequencing to detect measurable residual disease (MRD) in multiple myeloma patients at a sensitivity level of 10-5 or higher. The findings provide valuable insights for reporting MRD levels and comparing results between laboratories.
EXPERIMENTAL HEMATOLOGY
(2023)
Letter
Biophysics
Luca Vinci, Christian Flotho, Peter Noellke, Dirk Lebrecht, Riccardo Masetti, Valerie de Haas, Barbara De Moerloose, Michael Dworzak, Henrik Hasle, Tayfun Guengoer, Jan Stary, Dominik Turkiewicz, Marek Ussowicz, Cristina Diaz de Heredia, Jochen Buechner, Kirsi Jahnukainen, Krisztian Kallay, Ivana Bodova, Owen P. P. Smith, Marco Zecca, Dorine Bresters, Peter Lang, Tania Nicole Masmas, Roland Meisel, Herbert Pichler, Miriam Erlacher, Gudrun Goehring, Franco Locatelli, Brigitte Strahm, Charlotte M. M. Niemeyer, Ayami Yoshimi
BONE MARROW TRANSPLANTATION
(2023)
Article
Hematology
Peter Hokland, Shahina Daar, Wael Khair, Sujit Sheth, Ali T. Taher, Lorenza Torti, Chattree Hantaweepant, Deborah Rund
Summary: The thalassaemias are a group of genetic disorders of haemoglobin found worldwide. Standard treatment involves regular transfusions and iron chelation therapy. Innovative therapies like bone marrow transplantation and gene therapy are not widely available. This article discusses the management strategies for a refugee patient with beta thalassaemia in six countries, highlighting the disparities in available therapies and the challenges of ensuring adherence to treatment.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Sarah Weischendorff, Silvia De Pietri, Mathias Rathe, Thomas Leth Frandsen, Henrik Hasle, Claus H. Nielsen, Claus Moser, Klaus Mueller
Summary: This study investigated whether measurements of neutrophil chemotaxis could be used as risk markers for bloodstream infections (BSI) in children with acute lymphoblastic leukemia (ALL). The results showed that patients who developed BSI during induction treatment had increased levels of chemokines CXCL1 and CXCL8, suggesting that these markers may help identify patients at increased risk of BSI during chemotherapy-induced neutropenia.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Elisabeth Luna Hojlund, Oriane Cedile, Thomas Stauffer Larsen, Gayaththri Vimalathas, Michael Boe Moller, Marcus Hoy Hansen, Charlotte Guldborg Nyvold
Summary: This study evaluated the use of cfDNA from blood plasma to detect clonal B cells in DLBCL patients, and found that plasma cfDNA was superior in detecting clonal rearrangements compared to blood or bone marrow-derived cellular DNA. These findings validate blood plasma as a reliable and easily accessible source for detecting neoplastic cells in DLBCL.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
(2023)
Article
Endocrinology & Metabolism
Marta Diaz-delCastillo, Michael Tveden Gundesen, Christian Walther Andersen, Anne Lerberg Nielsen, Hanne Elisabeth Hojsgaard Moller, Pernille Just Vinholt, Jon Thor Asmussen, Ida Bruun Kristensen, Charlotte Guldborg Nyvold, Niels Abildgaard, Thomas Levin Andersen, Thomas Lund
Summary: Multiple myeloma is an incurable bone marrow cancer that leads to osteolytic lesions. Treatment often involves proteasome inhibitors, but their side effects and administration route limit long-term use. This study investigates the bone effects of ixazomib, a new-generation oral proteasome inhibitor, and suggests that it may promote bone formation by reducing bone resorption and promoting longer bone formation events.
JOURNAL OF BONE AND MINERAL RESEARCH
(2023)
Article
Medicine, Research & Experimental
Mette Ostergaard, Birgitte Sandfeld-Paulsen
Summary: Allergen-specific serum immunoglobulin E (SIgE) levels are important in allergy diagnostics. This study investigated the effect of different preanalytical factors on the stability of SIgE. The results showed that SIgE is stable for 48 hours at room temperature before centrifugation and for 10 days at 5°C after centrifugation. However, prolonged storage and repeated freeze-thaw cycles can result in variation in SIgE levels.
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION
(2023)
Article
Hematology
Peter Hokland, Isolda I. Fernandez, Sylvie D. Freeman, Bjorn T. Gjertsen, Jie Jin, Vidh Murthy, Masamitsu Yanada, Arnold Ganser
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Editorial Material
Hematology
Peter Hokland
Summary: This article explores how patients are handled within widely varying health systems, including both strained economies and more affluent ones, providing a global view.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Biographical-Item
Hematology
Peter Hokland
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Signe Neldeborg, Johannes Frasez Soerensen, Charlotte Thornild Moller, Marie Bill, Zongliang Gao, Rasmus O. Bak, Kasper Holm, Boe Sorensen, Mette Nyegaard, Yonglun Luo, Peter Hokland, Magnus Stougaard, Maja Ludvigsen, Christian Kanstrup Holm
Summary: Oncogenic fusion drivers in hematological cancers can be targeted using a new dual intron-targeting CRISPR-Cas9 treatment strategy. This strategy can efficiently disrupt fusion genes without requiring precise knowledge of the breakpoints in t(8;21) AML. In vitro and in vivo experiments showed significant reduction in cell growth and tumor growth in response to disruption of RUNX1-RUNX1T1. These findings were confirmed in primary cells from an AML patient.
Article
Oncology
Thomas N. N. Nissen, Catherine Rechnitzer, Birgitte K. K. Albertsen, Lotte Borgwardt, Vibeke B. B. Christensen, Eva Fallentin, Henrik Hasle, Lars S. S. Johansen, Lisa L. L. Maroun, Karin B. B. Nissen, Allan Rasmussen, Mathias Rathe, Steen Rosthoj, Nicolai A. A. Schultz, Peder S. S. Wehner, Marianne H. H. Jorgensen, Jesper Brok
Summary: This study reports the incidence, outcomes, and long-term adverse events of malignant liver tumors in Danish children over the past 35 years. The overall incidence of liver tumors in Danish children was approximately 2.29 per 1 million children per year, with hepatoblastoma being the most common tumor. The overall 5-year survival rate was 84% and 78% for hepatoblastomas and hepatocellular carcinomas, respectively, with age≥8 years being the most significant factor associated with a poorer prognosis. Adverse events included reduced renal and cardiac function, as well as impaired hearing function, affecting a significant number of patients.
Article
Hematology
Soren Thorgaard Bonlokke, Christian Fenger-Eriksen, Hans Beier Ommen, Anne-Mette Hvas
Summary: This study investigated the dynamics of fibrinolysis in patients with hematological cancer and found that patients with lymphoma exhibited impaired fibrinolysis, while patients with acute promyelocytic leukemia and light-chain amyloidosis showed hyperfibrinolysis.